ATAI Life Sciences led a $80m Series B round in COMPASS Pathways.

ATAI Life Sciences, a global biotech company builder, led a $80m Series B round in COMPASS Pathways, a mental health care company. The Series B funding comes from investors, such as Founders Fund, Able Partners, Camden Partners Nexus, Perceptive Advisors, Skyviews Life Science, and Soleus Capital. "We've been with the COMPASS team from the very beginning and share a goal of bringing innovation to those who suffer with mental illness. We believe COMPASS is setting a new standard for innovation in mental health care and we're proud to be playing a part in this," Florian Brand, ATAI Life Sciences CEO.